(Reuters) – Britain’s GlaxoSmithKline and South Korea’s SK Bioscience said on Tuesday the drugmakers have begun a late-stage clinical study of SK’s COVID-19 vaccine candidate in combination with GSK’s pandemic vaccine booster.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Shounak Dasgupta)
